Eli Lilly filed six federal lawsuits on August 12, 2026, against U.S. businesses it accuses of selling unapproved versions of retatrutide, an investigational obesity drug still in Phase 3 trials with no regulatory approval in any country. The complaints name Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co., and land in federal courts in California and Texas, CNBC reported on the filing date. The defendants span a compounding pharmacy, a medical spa, and online vendors that Lilly says marketed the triple-agonist molecule—targeting GIP, GLP-1, and glucagon receptors—directly to consumers seeking weight loss.
The suits arrive roughly a year before Lilly expects to submit retatrutide for FDA review. The company plans to file for approval early next year, Fierce Pharma reported, meaning every vial sold under the retatrutide name today sits outside any authorized access pathway. The FDA stated in June that sales of unapproved retatrutide to consumers are illegal and that the compound cannot lawfully be compounded under federal law.
From Referrals to Named Complaints
Lilly has spent months building a case file that extends well beyond six defendants. The company referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement agencies, and professional licensing boards. Separately, it reported more than 14,000 websites, advertisements, social media posts, and product listings marketing retatrutide across more than 100 countries to internet service providers, e-commerce platforms, and payment companies. The six lawsuits convert a portion of that enforcement apparatus into direct civil claims against named sellers, including grey market peptides vendors that Lilly says operate under a false "research use only" shield.
Four of the defendants—Astra Peptides, Legendary Peptides, Texas Peptides, and Lone Star Peptide—allegedly advertised retatrutide without requiring a prescription while directing products toward consumers. Lilly's complaints argue that labeling material "for research use" does not insulate a seller when surrounding marketing, dosing instructions, and sales practices demonstrate intended human use. Aesthetic Envy, the California med spa, promoted retatrutide on its website as a therapy that "outperforms today's leading medications," according to Lilly's filing, without disclosing that no regulator has approved the product. Striker Pharmacy allegedly compounded a version of the investigational drug.
Lilly Chief Medical Officer David Hyman called the products circulating under the retatrutide name "entirely unverified, unapproved and not worth the risk." Max Denning, Lilly's Associate Vice President for Global Patient Safety in Cardiometabolic Health, told reporters the company views the supply as frequently sourced from unregulated foreign manufacturers in facilities never inspected by the FDA. U.S. Customs and Border Protection intercepted more than 690 shipments containing over 31,000 units of illicit GLP-1 products during fiscal year 2025, a figure Lilly cited to frame the cross-border volume feeding domestic sales.
The Research-Use Defense and What Comes Next
The central legal question in all six complaints is whether "research use only" labeling survives scrutiny when the buyer is a patient holding a syringe. The FDA's position—that retatrutide cannot be compounded and that unapproved sales are illegal—predates these filings. But no court has yet tested Lilly's specific theory that marketing context overrides the research-use designation for an investigational molecule. The question of whether peptides are legal to sell under such designations has produced conflicting guidance across jurisdictions, and these cases may generate the first binding answers for the retatrutide supply channel.
Three defendants moved quickly. Lone Star Peptide, Texas Peptides, and Aesthetic Envy removed their webpages advertising retatrutide within two days of the filings. Legendary Peptides offered no immediate comment. The remaining defendants did not respond to requests for comment.
Lilly also called on social media companies, e-commerce platforms, payment processors, credit card networks, and shipping firms to cut off the infrastructure enabling retatrutide sales. The company framed the request publicly but has not confirmed any platform policy changes specific to the molecule. Lilly established a formal expanded access program for retatrutide in early August, making the drug available before approval to a limited number of patients meeting specific medical criteria who cannot enroll in a clinical trial.
The six complaints are now pending in federal courts in California and Texas. No injunctions or rulings have been issued. Lilly's next concrete step is the BLA submission expected early next year; until that application clears FDA review, every sale of a product labeled retatrutide for human use remains outside legal channels, and the civil cases will test whether a manufacturer can close that gap through private litigation before regulators act.
